Prime Medicine, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $4.6M | $3.0M | $0 | $0 | $0 | $5.2M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $160.6M | $155.3M | $147.9M | $86.7M | $70.6M | $3.0M |
| SG&A Expense | — | $52.3M | $50.2M | $43.4M | $29.8M | $13.9M | $3.2M |
| Operating Income | — | $-208.4M | $-202.5M | $-204.8M | $-116.5M | $-84.5M | $-932.0K |
| Operating Margin | — | -4,498.1% | -6,787.4% | — | — | — | -17.9% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $-279.0K | $-948.0K | $-486.0K | $1.9M |
| Net Income | — | $-201.1M | $-195.9M | $-198.1M | $-121.8M | $-165.4M | $-3.4M |
| Net Margin | — | -4,342.4% | -6,566.6% | — | — | — | -65.5% |
| EPS (Basic) | — | $-1.35 | $-1.65 | $-2.18 | $-1.40 | $-1.58 | $-0.04 |
| EPS (Diluted) | — | $-1.35 | $-1.65 | $-2.18 | $-1.40 | $-1.58 | $-0.04 |
| Shares Outstanding (Basic) | 180.6M | 148.8M | 118.6M | 91.0M | 101.7M | 116.8M | 118.8M |
| Shares Outstanding (Diluted) | 180.6M | 148.8M | 118.6M | 91.0M | 101.7M | 116.8M | 118.8M |
| Dividends Per Share | — | — | — | — | — | — | — |